Asia FX muted, dollar fragile as CPI data boosts Sept rate cut bets
AUDUBON, Pa. - Globus Medical, Inc. (NYSE:GMED), a $7.56 billion medical device company currently trading near its 52-week low, announced Tuesday the expansion of its Excelsius navigation capabilities with the introduction of its DuraPro oscillating system, designed to enhance procedural workflows in spine surgery. According to InvestingPro data, the company maintains strong financials with a healthy 4.45 current ratio.
The DuraPro system, part of the company’s Power Portfolio, utilizes oscillating technology that helps prevent soft tissue wrapping while maintaining a natural sensation similar to conventional spinning drills. According to the company, the system provides instruments for bone removal while incorporating features to help protect delicate tissue.
Key features of the DuraPro system include anti-skiving pilot hole drilling and brush attachments for discectomies. The system integrates with ExcelsiusGPS and ExcelsiusHub platforms to support both navigated and non-navigated surgical workflows.
Drs. Roland Kent and David Glassman of Axis Spine Center in Cour D’Alene, Idaho, who have used the system, stated, "DuraPro allows us to navigate around delicate structures with greater confidence during decompressions."
Globus Medical also launched Verzera, a navigated high-speed drill system that integrates with the company’s existing navigation technology platforms.
The company aims to address what it describes as a $550 million high-speed drill market with these new offerings. With revenue growth of 32.26% in the last twelve months, Globus Medical continues to expand its market presence. David Hole, president of spine at Globus Medical, said the oscillating system coupled with navigation enhances procedural solutions offered to surgeons.
Globus Medical develops and manufactures products for spine, orthopedic trauma, joint reconstruction, and related medical fields. The company is currently considered undervalued according to InvestingPro analysis, with investors anticipating the next earnings report on July 31. The information in this article is based on a company press release statement. For comprehensive analysis and additional insights, access the detailed Pro Research Report available on InvestingPro.
In other recent news, Globus Medical reported its first-quarter results for 2025, revealing unexpected shortfalls in revenue and earnings, primarily due to lower sales of Enabling Technology products and supply chain issues from integrating legacy products post-merger. The company posted sales of $598.1 million, slightly below expectations, with challenges in the Musculoskeletal segment and extended timelines in Enabling Technology deals contributing to the shortfall. Despite these hurdles, Globus Medical achieved a record level of free cash flow and successfully repaid all outstanding debt from the NuVasive merger, leaving it debt-free. In response to market valuation concerns, Globus Medical announced a $500 million stock buyback program, emphasizing its commitment to long-term shareholder value. Analyst reactions were mixed; Piper Sandler maintained an Overweight rating, while BTIG downgraded the stock to Neutral, citing challenges in the Spine business. JMP analysts retained a Market Perform rating, noting robust core business fundamentals despite initial headwinds. Oppenheimer adjusted its price target for Globus Medical from $90 to $78, maintaining a Perform rating due to the underwhelming first-quarter sales and increased competition in the robotic surgery space. As Globus Medical navigates these developments, its management remains optimistic about future quarters, although analysts express caution given the competitive landscape.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.